Ibrance and Feeding disorder - a phase IV clinical study of FDA data
Feeding disorder is found among people who take Ibrance, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Ibrance and have Feeding disorder. It is created by eHealthMe based on reports of 79,191 people who have side effects when taking Ibrance from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
79,191 people reported to have side effects when taking Ibrance.
Among them, 188 people (0.24%) have Feeding disorder.
What is Ibrance?
Ibrance has active ingredients of palbociclib. eHealthMe is studying from 79,273 Ibrance users for its effectiveness, alternative drugs and more.
What is Feeding disorder?
Feeding disorder (when children refuse to eat certain food groups) is found to be associated with 1,316 drugs and 816 conditions by eHealthMe.
Number of Ibrance and Feeding disorder reports submitted per year:
Time on Ibrance when people have Feeding disorder *:
Gender of people who have Feeding disorder when taking Ibrance*:
Age of people who have Feeding disorder when taking Ibrance *:
Common drugs people take besides Ibrance *:
Common side effects people have besides Feeding disorder *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Ibrance and have Feeding disorder?Check whether Feeding disorder is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Feeding disorder and when was it recovered:
Expand to all the drugs that have ingredients of palbociclib:
Alternative drugs to, pros and cons of Ibrance:
- Ibrance (79,273 reports)
Common Ibrance side effects:
- Fatigue (feeling of tiredness): 16,023 reports
- Hair loss: 6,928 reports
- Diarrhea: 5,821 reports
- Death: 4,821 reports
- Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 4,573 reports
- Weakness: 3,662 reports
Browse all side effects of Ibrance:a b c d e f g h i j k l m n o p q r s t u v w x y z
Feeding disorder treatments and more:
- Feeding disorder (15,001 reports)
COVID vaccines that are related to Feeding disorder:
- Feeding disorder in Moderna COVID Vaccine
- Feeding disorder in Pfizer BioNTech Covid Vaccine
- Feeding disorder in Johnson and Johnson Covid Vaccine
Common drugs associated with Feeding disorder:
- Aspirin: 858 reports
- Methotrexate: 782 reports
- Humira: 759 reports
- Prednisone: 758 reports
- Enbrel: 556 reports
- Omeprazole: 535 reports
- Tramadol: 509 reports
- Vitamin d: 503 reports
- Gabapentin: 480 reports
- Metformin: 441 reports
All the drugs that are associated with Feeding disorder:
- Feeding disorder (1,316 drugs)
Common conditions associated with Feeding disorder:
- Rheumatoid arthritis: 916 reports
- Pain: 701 reports
- Multiple sclerosis: 646 reports
- High blood pressure: 555 reports
- Crohn's disease: 472 reports
- Depression: 386 reports
- Diabetes: 361 reports
All the conditions that are associated with Feeding disorder:
- Feeding disorder (816 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on palbociclib (the active ingredients of Ibrance) and Ibrance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Prandin and Macular Degeneration - a second ago
- Dermatitis Contact and Myelodysplastic Syndrome - a second ago
- Hiccups and Calcium Deficiency - 19 seconds ago
- Vancomycin Hcl and Hepatotoxicity - 22 seconds ago
- Cognitive Disorder and pfizer biontech covid vaccine - 26 seconds ago
- Allegra-D 12 Hour vs. Omnaris - 28 seconds ago
- Irbesartan and Carafate drug interaction - 34 seconds ago
- Daunorubicin Hydrochloride and Hepatomegaly - 37 seconds ago
- Vitamin B9 and Cyclophosphamide drug interaction - 39 seconds ago
- Robaxin and Chronic Fatigue Syndrome - 40 seconds ago